Novelion Therapeutics Inc. Common Shares
NVLN
NVLN was delisted on the 8th of October, 2019.
35 hedge funds and large institutions have $5.35M invested in Novelion Therapeutics Inc. Common Shares in 2019 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 7 increasing their positions, 9 reducing their positions, and 5 closing their positions.
0% more funds holding
Funds holding: 35 → 35 (0)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 5
22% less repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 9
38% less capital invested
Capital invested by funds: $8.68M → $5.35M (-$3.33M)
46% less call options, than puts
Call options by funds: $46K | Put options by funds: $85K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
+$546K |
| 2 |
EIG
EdgePoint Investment Group
Toronto,
Ontario, Canada
|
+$456K |
| 3 |
Goldman Sachs
New York
|
+$288K |
| 4 |
Group One Trading
Chicago,
Illinois
|
+$53.6K |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$34.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BC
Broadfin Capital
New York
|
-$897K |
| 2 |
JAM
JW Asset Management
Miami Beach,
Florida
|
-$389K |
| 3 |
AG
Artal Group
Luxembourg
|
-$315K |
| 4 |
CCM
Context Capital Management
Lajolla,
California
|
-$52K |
| 5 |
Millennium Management
New York
|
-$42.7K |
NVLN Hedge Fund Activity: Q2 2019 in Review
35 of the 4,625 institutional investors tracked by Wall St. Rank reported a position in Novelion Therapeutics Inc. Common Shares (NVLN) for Q2 2019, worth a combined $5.35M — down 38% from $8.68M a quarter earlier.
Fund positioning in NVLN was balanced in Q2 2019: 5 funds opened new positions, 5 closed out, 7 added to existing stakes and 9 trimmed.
The largest buyer was Stonepine Capital Management, opening a new position worth an estimated $546K. The largest seller was Broadfin Capital, exiting entirely with an estimated $897K sold.
- 35 institutional investors held Novelion Therapeutics Inc. Common Shares (NVLN) as of Q2 2019, unchanged from Q1 2019.
- Funds reported $5.35M of Novelion Therapeutics Inc. Common Shares stock for Q2 2019, down 38% quarter-over-quarter.
- 5 funds opened new Novelion Therapeutics Inc. Common Shares positions in Q2 2019 and 5 closed out, a net change of 0 holders.
- The largest Novelion Therapeutics Inc. Common Shares buyer in Q2 2019 was Stonepine Capital Management, an estimated $546K added.
- The largest Novelion Therapeutics Inc. Common Shares seller in Q2 2019 was Broadfin Capital, an estimated $897K sold.
Based on aggregated 13F filings for Q2 2019.